Literature DB >> 34724091

Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.

Hui Li1,2, Miaofang Wu1, Zhuna Wu1, Jinxiao Liang1, Lijuan Wang1, Xi Yang3, Zhongqiu Lin4, Jing Li5,6.   

Abstract

PURPOSE: Epithelial ovarian cancer (EOC) is regarded as the deadliest gynecological cancer, and the demand for novel noninvasive prognostic biomarkers remains significant. This study aimed to investigate the prognostic value of preoperative blood biomarkers in EOC patients.
METHODS: In total, 73 patients who had undergone ovarian mass resection were enrolled. Serum concentration of biomarkers, including soluble interleukin 2 receptor α (sIL-2R), was measured 1-2 weeks before surgery. Independent prognostic factors for progression-free survival (PFS) were investigated with multivariate Cox regression analysis. A prognostic model was subsequently developed and evaluated by discrimination, calibration and clinical net benefit. Furthermore, transcriptome data of 376 EOC cases from The Cancer Genome Atlas (TCGA) were analyzed with ESTIMATE, CIBERSORT and Maftools algorithm to evaluate the correlation of IL2RA expression with tumor immune microenvironment and immunotherapeutic response.
RESULTS: High sIL-2R concentration was found to be the only significant prognostic blood biomarker for PFS by multivariate Cox regression analysis in our center. A prognostic nomogram was developed with satisfactory discrimination, calibration and clinical net benefit. In addition, higher IL2RA expression was significantly associated with higher immune scores, activated CD4+ T cells, M2 macrophages and resting dendritic cells in TCGA data. Furthermore, IL2RA expression was closely related to TMB scores.
CONCLUSIONS: sIL-2R is a potential prognostic immune biomarker for EOC patients, and a comprehensive prognostic model comprising sIL-2R with satisfactory discrimination and clinical appliance was developed. Therefore, we recommend routine sIL-2R testing in EOC patients.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Epithelial ovarian cancer; Immune biomarker; Prognostic; sIL-2R

Mesh:

Substances:

Year:  2021        PMID: 34724091     DOI: 10.1007/s00262-021-03092-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  42 in total

1.  Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Authors:  Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

Review 2.  Epithelial ovarian cancer.

Authors:  Stephanie Lheureux; Charlie Gourley; Ignace Vergote; Amit M Oza
Journal:  Lancet       Date:  2019-03-23       Impact factor: 79.321

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 4.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

Authors:  Stephanie Lheureux; Marsela Braunstein; Amit M Oza
Journal:  CA Cancer J Clin       Date:  2019-05-17       Impact factor: 508.702

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 8.  Ovarian Cancer Prevention and Screening.

Authors:  Usha Menon; Chloe Karpinskyj; Aleksandra Gentry-Maharaj
Journal:  Obstet Gynecol       Date:  2018-05       Impact factor: 7.661

9.  Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Authors:  György Sölétormos; Michael J Duffy; Suher Othman Abu Hassan; René H M Verheijen; Bengt Tholander; Robert C Bast; Katja N Gaarenstroom; Catharine M Sturgeon; Johannes M Bonfrer; Per Hyltoft Petersen; Hugo Troonen; Gian CarloTorre; Jan Kanty Kulpa; Malgorzata K Tuxen; Raphael Molina
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

10.  Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer.

Authors:  Ying Tang; Hui-Quan Hu; Fang-Xiang Tang; Dan Lin; Rui Shen; Li Deng; Ya-Lan Tang; Li-Hong Deng; Mi Zhou; Jun Li; Bin Su; Fan Xu
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.